Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499590 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
A Phase 3 study, sponsored by OPKO Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 338
- Enrollment target
NCT00499590 is a Phase 3 study that was terminated before completion, run by OPKO Health. The registered enrollment target is 338 participants.
The verdict
NCT00499590, a Phase 3 study, was terminated before completion, sponsored by OPKO Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 338 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with wet AMD. Patients will be assigned at random (like tossing a coin) to receive one of three treatments options for 104 weeks.
Interventions
- DRUG ranibizumab
- DRUG bevasiranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499590
The ClinicalTrials.gov registry entry for NCT00499590 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ranibizumab is the first listed.
NCT00499590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499590 about?
NCT00499590 is a clinical study titled "Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD". The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with wet AMD. Patients will be as...
What is the current status of trial NCT00499590?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2007-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00499590?
The interventions under investigation include: ranibizumab (DRUG), bevasiranib (DRUG).
Who is sponsoring clinical trial NCT00499590?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.